David J. FitzGerald - Concepedia

Author

David J. FitzGerald

Also Known As

D J FitzGerald, D. J. P. FitzGerald, D.J. FITZGERALD, D.J. FitzGERALD, D.J. FitzGerald, D.J. Fitzgerald, DAVID J.P. FITZGERALD, David J FitzGerald, David J. FitzGerald, David J. Fitzgerald

101

Publications

7.3K

Citations

H-Index

Concepts

All Affiliations

National Cancer Institute National Institutes of Health Center for Cancer Research MRC Laboratory of Molecular Biology

About

David J. FitzGerald is an author at National Cancer Institute specializing in medicine, immunology, and microbiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	22	26	2.3K
2	Natural Sciences	5	5	251
3	Allergy	5	5	318
4	Biochemistry	4	4	200
5	Engineering	1	1	83

David J. FitzGerald

Publications

5.6K

Citations

H-Index

Page 1

	Year	Citations
Anti-CD22–chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia Waleed Haso, Daniel W. Lee, Nirali N. Shah, Blood	2012	576
Efficacy of the Anti-CD22 Recombinant Immunotoxin BL22 in Chemotherapy-Resistant Hairy-Cell Leukemia Robert J. Kreitman, Wyndham H. Wilson, Karen Bergeron, New England Journal of Medicine	2001	508
Identification of tandem duplicate regulatory small RNAs in <i>Pseudomonas aeruginosa</i> involved in iron homeostasis Paula J. Wilderman, Nathaniel A. Sowa, David J. FitzGerald, Proceedings of the National Academy of Sciences	2004	445
A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin Vijay K. Chaudhary, Gary Queen, Richard P. Junghans, Nature Microbial ToxinToxinologyMedicineVirulence FactorPathogenesis	1989	418
Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia Robert J. Kreitman, Martin S. Tallman, Tadeusz Robak, Journal of Clinical Oncology	2012	296
Phase I Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With B-Cell Malignancies Robert J. Kreitman, David Squires, Maryalice Stetler‐Stevenson, Journal of Clinical Oncology	2005	256
Selective killing of HIV-infected cells by recombinant human CD4-Pseudomonas exotoxin hybrid protein Vijay K. Chaudhary, Tamio Mizukami, Thomas R. Fuerst, Nature Selective KillingHuman RetrovirusHiv-infected CellsImmunologyAntiviral Response	1988	254
Adenovirus-induced release of epidermal growth factor and pseudomonas toxin into the cytosol of KB cells during receptor-mediated endocytosis David J. FitzGerald, R. Padmanabhan, Ira Pastan, Cell Cell PhysiologySignal TransductionPathogenesisImmunologyEndocytic Pathway	1983	254
Phase I Trial of Continuous Infusion Anti-Mesothelin Recombinant Immunotoxin SS1P Robert J. Kreitman, Raffit Hassan, David J. FitzGerald, Clinical Cancer Research	2009	218
Phase II Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With Hairy Cell Leukemia Robert J. Kreitman, Maryalice Stetler‐Stevenson, Inger Margulies, Journal of Clinical Oncology	2009	213

Page 1